Related Experiment Videos
[Possibilities in drug therapy in prostatic carcinoma]
1Clinique urologique, Centre hospitalier universitaire Bichat, Paris.
Therapeutische Umschau. Revue Therapeutique
|June 1, 1995
Summary
Advanced prostate cancer treatment focuses on palliative care and symptom management. Hormone withdrawal is the primary drug therapy, with orchiectomy and LH-RH analogues being effective options for advanced prostate cancer.
Area of Science:
- Oncology
- Urology
Context:
- Two-thirds of prostate cancers are diagnosed at advanced stages, beyond local curative treatment.
- Current drug treatments for advanced prostate cancer are palliative, aiming to manage complications rather than improve survival.
Purpose:
- To review current drug therapy strategies for advanced prostate cancer.
- To discuss the efficacy and limitations of various hormonal and chemotherapeutic interventions.
Summary:
- Hormone withdrawal, via orchiectomy or LH-RH analogues, is the first-line systemic therapy, achieving favorable responses in 70-80% of patients.
- Estrogens are rarely used due to cardiovascular risks. Antiandrogens are typically used in combination for total androgen suppression.
- Chemotherapy offers limited efficacy, with temporary remission in only 10-20% of patients with hormone-refractory prostate cancer.
Impact:
- Highlights the palliative nature of current advanced prostate cancer treatments.
- Underscores the need for more effective systemic therapies and clarifies the role of hormonal manipulation and chemotherapy.